Arizona Marijuana Consulting Firm Acquired By Item 9 Labs

One of the longest-operating cannabis consulting firms in Arizona, Dispensary Permits, has been acquired by publicly traded corporation Item 9 Labs for $1.5 million and 3 million shares of stock.

Here are the basics of the deal:

Item 9 Labs (OTC: INLB) said in a news release the agreement includes ownership of websites dispensarypermits.com and dispensarytemplates.com, along with all the intellectual property held by Scottsdale-based Dispensary Permits and its owner, Sara Gullickson.
Item 9, based in Phoenix, already owns and operates a 50-acre medical marijuana cultivation site.
Gullickson founded Dispensary Permits in 2010 and since then has helped clients win plant-touching business licenses in more than 12 states.

Gullickson has also been tapped by Item 9 to be the company’s new CEO for at least the next three years – subject to an employment agreement.

Item 9 CEO Bryce Skalla will transition into the firm’s presidency. Gullickson also was appointed to Item 9’s board of directors.

Original Article Source: https://mjbizdaily.com/arizona-marijuana-consulting-firm-acquired-by-item-9-labs/

Comments

Could CBD Lead To The Development Of Safer Antipsychotic Medications?

Antipsychotic medications are important for managing a number of different psychiatric ailments, including bipolar disorders, schizophrenia, and even dementia. These drugs can greatly improve the manageability of symptoms that often distort one’s experience of reality. They can also create major mood disruptions and lead to a number of behavioral and emotional difficulties. Antipsychotic and anti-psychosis medications can be life-changing for people with such disorders, enabling them to live more normal and manageable lives without their symptoms taking over. These drugs work by regulating neurotransmitters in the brain so that naturally occurring imbalances and dysfunctions no longer disrupt mental and emotional processes. Often, reaching this outcome is much easier said than done; it can take a lot of time to find courses and combinations of treatments that work. It’s sometimes necessary to make adjustments to find the right balance for the individual and it’s not unusual for outc...

Can Medical Marijuana Help Aging Parents With Dementia?

For decades, marijuana, even for medical uses, was demonized or questioned. When states like Colorado legalized it for recreational use, more studies began to determine provable efficacy for its use as a medicine. The Federal government still classifies marijuana the same way it classifies heroin: harmful and with no medical benefits. Now we can see that this is wrong. When states legalized marijuana, referred to as cannabis here, they had an interest in getting data to see what good it could do. Proving efficacy could increase medical marijuana sales, benefit people who might at least find some medical use, and overall would bring tax dollars into the state coffers. Without funding studies, the Federal government has done very little to demonstrate what good cannabis can do. After all, if the presumption is that it helps nothing, there would be no motivation to determine with scientific data that it does anyone any good. But we have convincing data now about its beneficial use ...

Cannabis Watch: Canopy Growth To Book Charge Of Up To $568 Million As Marijuana Restructuring Continues

Canopy Growth Corp. said early Thursday it was halting a range of operations across three continents and expects its restructuring plans to result in a charge of up to C$800 million (567.9 million) in the fiscal fourth quarter. U.S.-traded shares US:CGC CA:WEED of the cannabis company fell 1.9% in afternoon trading. Canopy said it was selling operations in Africa, curtailing cultivation of hemp in the U.S. and Columbia, and shutting down an indoor production facility in Canada. The announcement will result in 85 job cuts, the company said. “When I arrived at Canopy Growth in January, I committed to conducting a strategic review in order to lower our cost structure and reduce our cash burn,” Canopy Chief Executive David Klein said in a statement. Read: As cannabis industry stays largely quiet on coronavirus, this CEO has been sounding the alarm Canopy’s restructuring announcement was expected by investors, Cowen analyst Vivien Azer wrote in a note to clients Thursday. Azer rate...

Norma Pence

Search This Blog